Log In

 
Company : Boehringer Ingelheim 
Thursday, October 8, 2015 1:50PM IST (8:20AM GMT)
 
(BW)(BOEHRINGER-INGELHEIM)
Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists1
Nearly 9 out of 10 pulmonologists surveyed believe a delay in IPF diagnosis negatively impacts patientsSlowing disease progression is considered the priority when selecting a pharmaceutical treatmentBreathlessness and lung function are top of mind when pulmonologists think about the impact of IPF1
 
Ingelheim, Germany

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. 79% stated that delayed diagnosis will delay initiating treatment that slows disease progression.1

 

IPF is a progressive and life threatening lung disease.2 Diagnosis of IPF is challenging, requiring a series of specific diagnostic tests with the median time from first symptoms to diagnosis between one and two years.2,3,4 Initial misdiagnosis occurs in around half of patients because symptoms are similar to other respiratory diseases like chronic obstructive pulmonary disease (COPD), asthma and congestive heart failure.4 However over 80% of patients with IPF have a distinctive, Velcro-like crackling sound that can be detected through a stethoscope.5

 

The survey showed that slowing disease progression is considered the biggest benefit of initiating treatment when IPF is first diagnosed (81%) and pulmonologist’s primary reason for selecting a pharmaceutical treatment for IPF (78%). Improving patient quality of life was the second highest motivation for pulmonologists when selecting an IPF treatment (63%).1

 

In addition to asking pulmonologists about their approaches to treatment, the survey asked participants to consider IPF from the patient’s perspective, including impact of the disease. When asked what was most important for an IPF patient to understand in terms of knowing how IPF will affect them, 77% of pulmonologists stated ‘knowing what treatment options are available for IPF’, and 68% said ‘knowing that IPF is unpredictable and that their condition could change suddenly and unexpectedly’.

 

Top of mind for physicians when thinking about the impact of IPF were breathlessness (54%), lung function (21%) and exacerbations (13%).1 As IPF progresses lung function gradually and irreversibly declines leading to difficulty breathing and decreased oxygen supply to the major body organs.6 Exacerbations – events of acute respiratory worsening – are a risk to all IPF patients and they can occur at any time during the course of the disease without warning or known cause.7 Acute exacerbations can impact the course of the disease, often leading to death within a few months, making them a crucial treatment consideration for pulmonologists managing IPF patients.8

 

“As someone who talks every day to people with IPF, it is fascinating to see how pulmonologists view and prioritise the impact of the disease on patients and make treatment decisions,” said Dagmar Kauschka, Chairperson of the German patient advocacy group Lungenfibrose e.V.. “We put a lot of time and energy into supporting IPF patients over their day-to-day concerns such as breathlessness and the risk of exacerbations. One of our goals is to fight for patient support as a regular part of therapy. We are reassured to see through this survey that pulmonologists do recognise the key concerns when thinking about the impact of IPF on their patients.”

 

~ ENDS ~

 

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/08_oktober_2015_ipf.html

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

 

 

 

 

 

 

 
For News Release background on Boehringer Ingelheim click here
 
Media Contact Details
CONTACTS : Boehringer Ingelheim Corporate Communications Media + PR Dr Kristin Jakobs Phone: +49 6132 77 144553 Fax: +49 6132 – 77 6601 Email: press@boehringeringelheim.com
 
 
Submit your press release
More News from Boehringer Ingelheim

22/06/2017 11:20AM

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients

Boehringer Ingelheim today announced findings from GLORIA™-AF which show that people with non-valvular atrial fibrillation (AF) with few or no symptoms are more likely to have had a stroke prior to AF diagnosis ...

14/06/2017 7:57PM

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and ...

05/06/2017 9:50PM

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the ...

Similar News

27/06/2017 6:40PM

31 मार्च 2017 को समाप्त वित्त वर्ष के लिए टैरो की वार्षिक रिपोर्ट फॉर्म 20-एफ पर उपलब्ध

टैरो फार्मास्यूटिकल इंडस्ट्रीज लिमिटेड (एनवाईएसई:टैरो) ने आज एलान किया कि 31 मार्च 2017 को समाप्त वित्त वर्ष के लिए सिक्यूरिटीज एंड एक्सचेंज कमीशन (“एसईसी”) में दाखिल उसकी वार्षिक रिपोर्ट फॉर्म ...

No Image

23/06/2017 7:15PM

Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission (the ...